Somewhat Positive Press Coverage Somewhat Unlikely to Impact Psychemedics (PMD) Stock Price

Headlines about Psychemedics (NASDAQ:PMD) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Psychemedics earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave news articles about the company an impact score of 47.4012977706623 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Psychemedics opened at $20.70 on Friday, MarketBeat Ratings reports. The firm has a market cap of $112.64 million, a PE ratio of 23.85 and a beta of 0.75. The company has a current ratio of 3.01, a quick ratio of 3.01 and a debt-to-equity ratio of 0.11. Psychemedics has a 12-month low of $15.99 and a 12-month high of $27.99.

Psychemedics (NASDAQ:PMD) last announced its earnings results on Wednesday, March 7th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $9.76 million for the quarter. Psychemedics had a return on equity of 26.72% and a net margin of 14.52%.

The business also recently announced a quarterly dividend, which was paid on Friday, May 18th. Stockholders of record on Tuesday, May 8th were given a dividend of $0.18 per share. The ex-dividend date was Monday, May 7th. This is a positive change from Psychemedics’s previous quarterly dividend of $0.15. This represents a $0.72 dividend on an annualized basis and a dividend yield of 3.48%.

Psychemedics Company Profile

Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time.

Insider Buying and Selling by Quarter for Psychemedics (NASDAQ:PMD)

Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with's FREE daily email newsletter.

Leave a Reply